Should I Buy CNMD? CNMD 2026 Analysis

Should You Buy Conmed Corp (CNMD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

41.520

1 Day change

2.12%

52 Week Range

68.460

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient buyer: the broader trend is still bearish (SMA_200 > SMA_20 > SMA_5) and there are no Intellectia entry signals to justify chasing today’s bounce.
Near-term upside exists if price can break and hold above ~42.08 (R1), but current indicators suggest rallies may fade before that level is cleared.
Best stance here is to avoid initiating a new position at 40.64 until the chart structure improves (trend reversal confirmation).

Technical Analysis

Trend: Bearish overall (SMA_200 > SMA_20 > SMA_5), indicating the stock is still in a downtrend despite today’s +4.49% move.
Momentum: MACD histogram at -0.327 (below zero) and only contracting—selling pressure is easing, but not yet a bullish reversal.
RSI (6): 39.54, leaning weak/near-oversold territory; this can support short bounces but doesn’t confirm a sustained uptrend.
Key levels: Pivot 39.29 (must hold to avoid renewed weakness); Resistance R1 42.08 then R2 43.80; Support S1 36.50.
Pattern-based stats (similar candles): modest edge for the next week (+3.29%) but flat-to-slightly negative next month (-0.01%), consistent with a choppy bear-market bounce profile.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning/Sentiment: Open interest put/call ratio 0.33 is call-heavy (bullish bias in positioning), but today’s option volume is extremely low (only 3 puts, 0 calls), so the “bullish” read is weak/low-confidence.
Volatility: 30D IV ~52.0 vs historical vol ~36.4 (IV elevated), suggesting the market is pricing higher uncertainty; IV percentile ~69 indicates relatively rich option premiums.
Takeaway: Options data does not provide strong real-time confirmation of bullish sentiment due to negligible trading volume today.

Technical Summary

Sell

Buy

Positive Catalysts

- Q4 2025 sales grew +7.9% YoY to $373.2M; full-year sales $1.375B (solid top-line momentum).
- Supply chain improvement signals: sports medicine backorders/SKU counts at a three-year low.
- Strategic move: exiting gastro product lines is expected to improve long-term gross margins (~+80 bps).

Neutral/Negative Catalysts

- Profitability deterioration in the latest quarter: net income and EPS down ~50% YoY, and gross margin down ~1.29% YoY.
- Exit from gastro is described as margin-accretive but EPS-dilutive in 2026 (near-term earnings headwind).
- Chart remains in a bearish trend; today’s pop can be a counter-trend bounce rather than a durable reversal.

Financial Performance

Latest quarter: 2025/Q4.
Revenue: $373.2M, +7.88% YoY (growth is intact).
Profitability: Net income $16.74M, -50.41% YoY; EPS $0.54, -50.00% YoY (earnings pressure).
Margins: Gross margin 56.59%, down 1.29% YoY (not yet showing the benefits implied by the portfolio shift).
Outlook (company guidance): 2026 revenue $1.345B–$1.375B and adjusted EPS $4.30–$4.45 (guidance provides a framework but includes dilution from the product-line exit).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent analyst trend: price targets have been cut meaningfully (BofA $65→$52, Piper $68→$55, JPM $58→$52), reflecting lowered confidence/near-term headwinds.
Ratings mix: two Neutrals (BofA, JPM) vs one Overweight (Piper) — Street view is cautious overall.
Wall Street pros: steady execution/supply improvements; portfolio actions to enhance long-term margins.
Wall Street cons: earnings pressure (EPS dilution from gastro exit; recent EPS cuts), and muted enthusiasm implied by repeated PT reductions.
Influential/Political trading: No recent congress trading data available; hedge funds and insiders are reported as Neutral with no significant recent trend.

5 Analyst Rating

Wall Street analysts forecast CNMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNMD is 50 USD with a low forecast of 41 USD and a high forecast of 55 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

4 Hold

0 Sell

Hold

Current: 40.660

Low

Averages

High

Current: 40.660

Low

Averages

High

BofA

Neutral

downgrade

$65 -> $52

AI Analysis

2025-12-07

Reason

BofA

Price Target

$65 -> $52

AI Analysis

2025-12-07

downgrade

Neutral

Reason

BofA lowered the firm's price target on Conmed to $52 from $65 and keeps a Neutral rating on the shares after the company said it will exit its gastroenterology product lines. The exit is accretive to gross margins but dilutive to earnings in 2026, the analyst tells investors in a research note.

Piper Sandler

Matt O'Brien

Overweight

downgrade

$68 -> $55

2025-11-06

Reason

Piper Sandler

Matt O'Brien

Price Target

$68 -> $55

2025-11-06

downgrade

Overweight

Reason

Piper Sandler analyst Matt O'Brien lowered the firm's price target on Conmed to $55 from $68 and keeps an Overweight rating on the shares. The firm notes the company reported Q3 results that were roughly in-line with its estimates on the top-and-bottom line. Management essentially kept its revenue guidance for the year unchanged but did lower EPS by three cents, Piper adds.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CNMD

Unlock Now

CNMD Should I Buy

CNMD Should I Buy

Should You Buy Conmed Corp (CNMD) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch